Our leading
AI-driven drug discovery pipeline

Leveraging the power of the Recursion OS, we are building an industry-leading pipeline of potential best-in-class and first-in-class therapeutic assets.

We focus on indications with high unmet need, including oncology and rare disease.

Target
Disease Indication
Late Discovery
Preclinical
Phase 1/2
Pivotal/Phase 3
Read More
Oncology
REC-617
CDK7
Advanced solid tumors
Status:
Phase 1/2
Designation
Population:

~185,0001

More...Less

REC-617 is a reversible, non-covalent small molecule CDK7 inhibitor being developed for the treatment of multiple advanced solid tumor indications. There are currently no CDK7 inhibitors approved by the FDA. The precision design of REC-617, resulting in high selectivity and optimized half-life, could distinguish it from other CDK7 inhibitors in development, by enabling the management of potential toxicities associated with CDK7 inhibition and maximizing on-target efficacy.

Read More

Learn more on clinicaltrials.gov.

1. Annual incidence for patient types eligible for inclusion in Phase 1/2 ELUCIDATE trial. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
View Poster
REC-1245
RBM39
Biomarker-enriched solid tumors and lymphoma
Status:
Phase 1
Designation
Population:

~100,000+2

More...Less

REC-1245 is a highly potent RBM39 degrader being developed for the treatment of biomarker-enriched solid tumor indications and lymphoma. RBM39 was identified using phenotypic insights by the Recursion OS, and is a novel target mimicking CDK12 loss. There are currently no RBM39 degraders approved by the FDA. Early preclinical data shows REC-1245 reduces viability in tumors characterized by replication stress and DNA repair vulnerabilities (DDR defects) across multiple solid tumor types, including MSI-H/dMMR, HRR altered cancers, and other tumors.

Read More

Learn more on clinicaltrials.gov

2. Addressable incidence with biomarker-enriched solid tumors and other select histologies. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
Watch Video
REC-3565
MALT1
B-cell malignancies
Status:
Phase 1
Designation
Population:

~41,0003

More...Less

REC-3565 is a small molecule MALT1 inhibitor, being developed for multiple hematology indications. There are currently no MALT1 inhibitors approved by the FDA. The precision design of REC-3565 has resulted in a well-balanced molecule with selectivity over UGT1A1, which distinguishes it from other MALT1 inhibitors in clinical development. Avoiding UGT1A1 inhibition can potentially reduce hyperbilirubinemia risk and allow a better combination profile with drugs that have known liver toxicity issues.

Read More

Learn more on euclinicaltrials.eu.

3. Annual incidence of relapsed/refractory chronic lymphocytic leukemia and B-cell lymphomas. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
View Poster
REC-4539*
LSD1
Small-cell lung cancer
Status:
Strategic pause
Designation
Population:

~45,0004

More...Less

*Note: Due to competitive landscape, REC-4539 is on strategic pause.

REC-4539 is the first LSD1 inhibitor designed to be both CNS-penetrant and reversible, and is being developed for multiple hematology and solid tumor indications, including small-cell lung cancer (SCLC) and acute myeloid leukemia (AML). There are currently no LSD1 inhibitors approved by the FDA. REC-4539’s combined properties distinguish it from other LSD1 inhibitors in development, with the potential to reduce adverse events seen from on-target platelet effects.

4. Annual incidence of extensive stage SCLC. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
View Poster
REC-7735
PI3Kα H1047R
Breast cancer
Status:
Preclinical
Designation
Population:

~11,0005

More...Less

REC-7735 is a PI3Kα H1047R mutant selective inhibitor being developed for the treatment of HER2- HR+ breast cancer where the PI3Kα-H1047R mutation is present. This highly selective inhibitor targets the most frequent PIK3CA mutation and a key driver of cancer. REC-7735 was designed to maximize the therapeutic window and to avoid dose-limiting hyperglycemia or other off-target AEs associated with wild-type PI3Kα inhibition. Preclinical models have shown tumor regression when used as a monotherapy treatment and when combined with standard of care.

5. Annual incidence of HR+ breast cancer patients with PIK3CA-H1047R mutation. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
Rare Diseases
REC-4881
MEK1/2
Familial adenomatous polyposis
Status:
Phase 2
Designation
Fast Track; US and EU Orphan Drug
Population:

~50K6

More...Less

REC-4881 is an orally bioavailable, non-ATP-competitive, allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in people living with FAP, a rare tumor predisposition syndrome. There are currently no FDA-approved therapies for the treatment of FAP. MEK1/2 inhibition to target FAP was identified using phenotypic insights by the Recursion OS.

Read More

Learn more on clinicaltrials.gov.

6. Prevalence for adult and pediatric population. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
View Poster
REC-102
ENPP1
Hypophosphatasia
Status:
Candidate profiling
Designation
Population:

>7,8007

More...Less

REC-102 is an orally available, small molecule ENPP1 inhibitor, being developed for the treatment of hypophosphatasia (HPP). HPP is a rare, potentially life-threatening genetic disease, characterized by impaired mineralization of bones and teeth. Inhibiting ENPP1 reduces inorganic pyrophosphate (PPi) levels which may restore the PPi and phosphate balance needed to promote bone mineralization. With our collaborators, we have shown that ENPP1 inhibition is safe and well-tolerated by preclinical models, and for the first time demonstrated that ENPP1 is a druggable target for later-onset HPP.

7. Estimated prevalence ranges of mild-moderate HPP based on ALPL gene variants of a European population.
View Poster
Our Partnerships

We partner with leading data & capability partners, and therapeutic partners to discover and develop new medicines across oncology, rare disease, neuroscience, immunology and inflammation. More on our partnerships →

Therapeutic Area
Highlights
Neuroscience & Immunology
First neuroscience phenomap in human cell context. One optioned GI oncology program continues to advance. Potential for up to 40 programs​
Oncology & Immunology
Milestones achieved across four distinct BIC and FIC discovery programs in 18 months; potential for several program milestones upcoming​
Oncology
Advancing multiple programs with previously “undruggable” targets to lead series milestones​
Oncology & Immunology
Multi-year collaboration to identify and advance first-in-class and best-in-class programs​

Leveraging the power of the Recursion OS, we are building an industry-leading pipeline of potential best-in-class and first-in-class therapeutic assets.

We focus on indications with high unmet need, including oncology and rare disease.

Oncology
REC-617
Advanced solid tumors
Phase 1/2
|
|
Target / MOA:

CDK7

Status:

Phase 1/2

Designation
Population:

~185,0001

REC-617 is a reversible, non-covalent small molecule CDK7 inhibitor being developed for the treatment of multiple advanced solid tumor indications. There are currently no CDK7 inhibitors approved by the FDA. The precision design of REC-617, resulting in high selectivity and optimized half-life, could distinguish it from other CDK7 inhibitors in development, by enabling the management of potential toxicities associated with CDK7 inhibition and maximizing on-target efficacy.

Read More

Learn more on clinicaltrials.gov.

1. Annual incidence for patient types eligible for inclusion in Phase 1/2 ELUCIDATE trial. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
View Poster
REC-1245
Biomarker-enriched solid tumors and lymphoma
Phase 1/2
|
|
Target / MOA:

RBM39

Status:

Phase 1

Designation
Population:

~100,000+2

REC-1245 is a highly potent RBM39 degrader being developed for the treatment of biomarker-enriched solid tumor indications and lymphoma. RBM39 was identified using phenotypic insights by the Recursion OS, and is a novel target mimicking CDK12 loss. There are currently no RBM39 degraders approved by the FDA. Early preclinical data shows REC-1245 reduces viability in tumors characterized by replication stress and DNA repair vulnerabilities (DDR defects) across multiple solid tumor types, including MSI-H/dMMR, HRR altered cancers, and other tumors.

Read More

Learn more on clinicaltrials.gov

2. Addressable incidence with biomarker-enriched solid tumors and other select histologies. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
Watch Video
REC-3565
B-cell malignancies
Phase 1/2
|
|
Target / MOA:

MALT1

Status:

Phase 1

Designation
Population:

~41,0003

REC-3565 is a small molecule MALT1 inhibitor, being developed for multiple hematology indications. There are currently no MALT1 inhibitors approved by the FDA. The precision design of REC-3565 has resulted in a well-balanced molecule with selectivity over UGT1A1, which distinguishes it from other MALT1 inhibitors in clinical development. Avoiding UGT1A1 inhibition can potentially reduce hyperbilirubinemia risk and allow a better combination profile with drugs that have known liver toxicity issues.

Read More

Learn more on euclinicaltrials.eu.

3. Annual incidence of relapsed/refractory chronic lymphocytic leukemia and B-cell lymphomas. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
View Poster
REC-4539*
Small-cell lung cancer
Preclinical
|
|
Target / MOA:

LSD1

Status:

Strategic pause

Designation
Population:

~45,0004

*Note: Due to competitive landscape, REC-4539 is on strategic pause.

REC-4539 is the first LSD1 inhibitor designed to be both CNS-penetrant and reversible, and is being developed for multiple hematology and solid tumor indications, including small-cell lung cancer (SCLC) and acute myeloid leukemia (AML). There are currently no LSD1 inhibitors approved by the FDA. REC-4539’s combined properties distinguish it from other LSD1 inhibitors in development, with the potential to reduce adverse events seen from on-target platelet effects.

4. Annual incidence of extensive stage SCLC. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
View Poster
REC-7735
Breast cancer
Late Discovery
|
|
Target / MOA:

PI3Kα H1047R

Status:

Preclinical

Designation
Population:

~11,0005

REC-7735 is a PI3Kα H1047R mutant selective inhibitor being developed for the treatment of HER2- HR+ breast cancer where the PI3Kα-H1047R mutation is present. This highly selective inhibitor targets the most frequent PIK3CA mutation and a key driver of cancer. REC-7735 was designed to maximize the therapeutic window and to avoid dose-limiting hyperglycemia or other off-target AEs associated with wild-type PI3Kα inhibition. Preclinical models have shown tumor regression when used as a monotherapy treatment and when combined with standard of care.

5. Annual incidence of HR+ breast cancer patients with PIK3CA-H1047R mutation. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
Rare Diseases
REC-4881
Familial adenomatous polyposis
Phase 1/2
|
|
Target / MOA:

MEK Inhibitor

Status:

Phase 2

Designation
Fast Track; US and EU Orphan Drug
Population:

~50K6

REC-4881 is an orally bioavailable, non-ATP-competitive, allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in people living with FAP, a rare tumor predisposition syndrome. There are currently no FDA-approved therapies for the treatment of FAP. MEK1/2 inhibition to target FAP was identified using phenotypic insights by the Recursion OS.

Read More

Learn more on clinicaltrials.gov.

6. Prevalence for adult and pediatric population. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
View Poster
REC-102
Hypophosphatasia
Preclinical
|
|
Target / MOA:

ENPP1

Status:

Candidate profiling

Designation
Population:

>7,8007

REC-102 is an orally available, small molecule ENPP1 inhibitor, being developed for the treatment of hypophosphatasia (HPP). HPP is a rare, potentially life-threatening genetic disease, characterized by impaired mineralization of bones and teeth. Inhibiting ENPP1 reduces inorganic pyrophosphate (PPi) levels which may restore the PPi and phosphate balance needed to promote bone mineralization. With our collaborators, we have shown that ENPP1 inhibition is safe and well-tolerated by preclinical models, and for the first time demonstrated that ENPP1 is a druggable target for later-onset HPP.

7. Estimated prevalence ranges of mild-moderate HPP based on ALPL gene variants of a European population.
View Poster
Partnerships

We partner with leading data & capability partners, and therapeutic partners to discover and develop new medicines across oncology, rare disease, neuroscience, and immunology & inflammation. More on our partnerships →

Neuroscience & Immunology
First neuroscience phenomap in human cell context. One optioned GI oncology program continues to advance. Potential for up to 40 programs​
Oncology & Immunology
Milestones achieved across four distinct BIC and FIC discovery programs in 18 months; potential for several program milestones upcoming​
Oncology
Advancing multiple programs with previously “undruggable” targets to lead series milestones​
Oncology & Immunology
Multi-year collaboration to identify and advance first-in-class and best-in-class programs​
Expanded Access Policy
Expanded Access Policy

At Recursion Pharmaceuticals, we are committed to radically improving the lives of patients and their families by developing therapies that will make a lasting, positive, and transformative impact on diseases and conditions for which there are high unmet needs.

We believe that the best way to succeed in our mission is through well-designed clinical trials that determine the safety and effectiveness of investigational medicines. We understand that in some rare and specific circumstances, when enrollment into a clinical trial is not possible, physicians caring for patients with serious or life-threatening conditions or diseases may seek special access to investigational medicines. When appropriate and through an expanded access protocol, Recursion will consider individual Expanded Access, sometimes called “Compassionate Use” or “Early Access”, requests for an investigational medicine outside of an ongoing clinical trial for the indication being investigated by the company.

There may be additional requirements, but to start, a licensed treating physician must submit the request for Expanded Access in writing by contacting ExpandedAccess@Recursion.com. The physician must be able and willing to obtain a treatment IND, or regional equivalent, and Institutional Review Board or Ethics Committee approval, for the patient prior to initiating treatment with our investigational medicine.

We will consider applications to provide the investigational drug that will not, among other things, compromise the scientific validity of our broader development programs, or interfere with or delay clinical trials or regulatory filings designed to make the drug available to a larger patient population.

We endeavor to respond to Expanded Access requests within one week after the steps for submission are completed.

It is important to remember that investigational medicinal products have not yet received regulatory approval; thus, their potential risks and benefits are not yet established. Physicians and patients should consider all possible benefits and risks when seeking access to an investigational medicinal product. For information on available clinical trials visit: www.ClinicalTrials.gov.

Clinical Trial Transparency
Clinical Trial Transparency

Recursion is committed to maintaining the highest level of integrity and ethics across all clinical trials and investigational programs, including the timely and transparent disclosure of clinical trial information and results.

All company-sponsored Phase 2 and 3 clinical trials are posted on country-specific registries of clinical trials, such as clinicaltrials.gov. As part of our commitment to advancing science in the therapeutic areas in which we work, Recursion discloses results of these trials on public registries within 12 months following the trial completion date. To keep our patients informed, clinical trial results will be made available to participants in that trial upon request. Additionally, Recursion aims to submit an abstract of the primary analysis of clinical trial results for publication regardless of trial outcome or regulatory approval status.

FROM BIOTECH TO TECHBIO

By leveraging technology at every step of the process, we can accelerate the development of high potential drug candidates once we have validated their potential.

Our approach
© 2025 Recursion. All rights reserved.